Recently, the FDA granted approval to nanoparticle albumin-bound sirolimus (nab-sirolimus) for the treatment of patients with metastatic malignant perivascular epithelioid cell tumor (PEComa). Dr. Richard F. Riedel, Associate Professor of Medicine at Duke University, was one of the investigators of the AMPECT study, on which the approval was based. In this interview, Dr. Riedel speaks with Oncology Data Advisor about the significance of the approval of nab-sirolimus for the treatment of patients...
The FDA has approved daratumumab plus hyaluronidase-fihj (Darlazex Faspro®, Janssen Biotech) in combination with carfilzomib (Kyprolis®, Amgen) plus dexamethasone for patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior lines of therapy. "Daratumumab is a human immunoglobulin G kappa monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action," wrote Ajai Chari, MD, Professor of Medicine, Hematology, and Medical Oncology at ...
The FDA has approved sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro™, Aadi Bioscience) for patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor. "Malignant perivascular epithelioid cell tumor is a rare, aggressive sarcoma," wrote Andrew J. Wagner, MD, PhD, Medical Director of Ambulatory Oncology at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School, and colleagues, in t...
The FDA has approved pembrolizumab (Keytruda®, Merck) for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy with resection of metastatic lesions."Patients with renal cell carcinoma who undergo nephrectomy [had] no options for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting evidence [prior to this approval]," wrote Toni K. Choueiri, MD, Director of the Ki...
The FDA has approved ropeginterferon alfa-2b-njft (Besremi®, PharmaEssentia) for patients with polycythemia vera, marking the first approval of interferon therapy specifically for patients with polycythemia vera and the first treatment for all patients with polycythemia vera, regardless of their prior treatment history. "Ropeginterferon alfa-2b is a novel long-acting monopegylated IFN-alpha-2b," wrote Heinz Gisslinger, MD, Professor of Hematology at the Medical University of Vienna, Austria, and...
Anne Chiang, MD, PhD.
Patients with extensive-stage small cell lung cancer (SCLC) are experiencing better survival rates than they have in past years. In honor of Lung Cancer Awareness Month, Anne Chiang, MD, PhD, Chief Integration Officer and Deputy Chief Medical Officer of Smilow Cancer Hospital and Associate Professor in the Section of Medical Oncology at Yale School of Medicine, discusses recent developments that have led to improvements in survival rates, as well as also exciting new developments to come in the treatment of patients with extensive-stage small cell lung cancer.
The FDA has granted accelerated approval to asciminib (Scemblix®, Novartis AG) for patients with Philadelphia chromosome–positive (Ph-positive) chronic myeloid leukemia (CML) who have disease in chronic phase and were previously treated with two or more tyrosine kinase inhibitors and for those whose disease is in chronic phase with the T315I mutation."Patients with CML in chronic phase CML resistant or intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outco...
In this interview, Tricia Trammell, BA, CRA, FAHRA, R.T. (R)(M)(QM)(BS), CN-BI, Breast Center Manager at UT Southwestern Simmons Comprehensive Cancer Center, discusses the advancements in breast imaging in relation to screening for breast cancer.
Oncology Data Advisor™ · Perspectives on Metastatic and Castration-Resistant Prostate Cancer With Ulka Vaishampayan, MD Selma Khenissi, MPS: Hello, welcome to Oncology Data Advisor. I'm Selma Khenissi from i3 Health. In honor of prostate cancer awareness month, we are here today with Dr. Ulka Vaishampayan, who will be discussing issues surrounding prostate cancer. Welcome. Ulka Vaishampayan, MD: Thank you for having me on this interview. I would like to bring our problems surroundin...
In this interview, Deborah E. Farr, MD, Associate Professor in the Department of Surgery at the UT Southwestern Simmons Comprehensive Cancer Center, discusses the benefits of recent advances in the surgical treatment of breast cancer. She also gives insight into how breast cancer surgery may continue to evolve in the coming years and shares advice for counseling patients with breast cancer who are undergoing surgery. This interview has been conducted in partnership with the National Breast ...
The FDA has granted approval to atezolizumab (Tecentriq®, Genentech) for the adjuvant treatment of patients with stage II to IIIA non–small cell lung cancer (NSCLC) whose tumors have a programmed death ligand 1 (PD-L1) expression on ≥1% of tumor cells. Atezolizumab is approved for use following resection and platinum-based chemotherapy in this patient population.The FDA has also approved the VENTANA PD-L1 (SP263) Assay (Ventana Medical Systems), a diagnostic device that will select patients with...
The FDA has granted approval to pembrolizumab (Keytruda®, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express programmed death-ligand 1 (PD-L1). The FDA has also granted regular approval to single-agent pembrolizumab for patients with recurrent or metastatic cervical cancer whose tumors express PD-L1, with a combined positive score of ≥1, who experienced disease progression on or after c...
Teresa Knoop, MSN, RN, AOCN®.
At the Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit in Los Angeles, California, Teresa Knoop, MSN, RN, AOCN® gave a presentation on updates surrounding pharmacology. Oncology Data Advisor followed up with her, asking for advice on how to provide optimal pharmacological care for patients with cancer.
Tricia Trammell, BA, CRA, FAHRA, R.T. (R)(M)(QM)(BS), CN-BI.
In this interview, Tricia Trammell, BA, CRA, FAHRA, R.T. (R)(M)(QM)(BS), CN-BI, Breast Center Manager at UT Southwestern Simmons Comprehensive Cancer Center, discusses the advancements in breast imaging in relation to screening for breast cancer.
The FDA has granted approval to cetuximab (Erbitux®, Eli Lilly), in combination with encorafenib (Braftovi®, Array BioPharma) for the treatment of patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation. "Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy," wrote Scott Kopetz, MD, PhD, FACP, Professor in the Department of Gastrointestinal Medical ...
Selma Khenissi, MPS: Hello, welcome to Oncology Data Advisor. I'm Selma Khenissi from i3 Health. In honor of prostate cancer awareness month, we are here today with Dr. Ulka Vaishampayan, who will be discussing issues surrounding prostate cancer. Welcome. Ulka Vaishampayan, MD: Thank you for having me on this interview. I would like to bring our problems surrounding prostate cancer to the forefront today. Especially with this being Prostate Cancer Awareness Month, we should be thinking about the...
The FDA has approved ruxolitinib (Jakafi®, Incyte) for adult and pediatric patients 12 year of age and older with chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy."Chronic graft-versus-host disease, a major complication of allogeneic stem cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in approximately 50% of patients," wrote Robert Zeiser, MD, Professor and Head of the Tumor Immunology and Immune Modulation at th...
The FDA has granted approval to cabozantinib (Cabometyx®, Exelixis) for the treatment of patients with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)–targeted therapy and who are 12 years of age and older and ineligible or refractory to radioactive iodine."Patients with radioiodine-refractory DTC previously treated with VEGFR-targeted therapy have aggressive disease and no available standa...
The FDA has approved mobocertinib (Exkivity™, Takeda) for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.In addition, the FDA has approved the OncomineTM Dx Target Test (Life Technologies Corporation) as a companion diagnostic device to determine eligibility for treatment with mobocertinib."EGFR exon 20 insertion mutations ...
The FDA has granted approval to zanubrutinib (Brukinsa®, BeiGene) for the treatment of patients with Waldenstrom macroglobulinemia (WM). "Bruton tyrosine kinase (BTK) inhibition is an emerging standard of care for WM," wrote Constantine Si Lun Tam, MBBS, MD, FRACP, FRCPA, Professor at the Peter MacCallum Cancer Centre in Australia, and colleagues, in their publication of the ASPEN study results (NCT03053440), on which the approval was based. "ASPEN is a randomized phase 3 study comparing zanubru...